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Abstract
Background: To assess the outcome of patients with stable angina pectoris treated with
percutaneous coronary intervention versus medically treated patients.
Methods: Eighty patients with stable angina pectoris and coronary stenosis as confirmed in
coronary angiography were treated with (n = 31) or without (n = 49) percutaneous coronary
intervention in our department. All patients received optimal medical therapy and were fol-
lowed up for a period of 24 months.
Results: Baseline clinical characteristics, including risk factors of coronary heart disease
and coronary lesion type did not differ between the two groups (all p > 0.05). There was no
significant difference in major adverse cardiac events (22.4% vs. 22.6%) during the 24 month
follow-up between the two groups (p > 0.05).
Conclusions: Percutaneous coronary intervention did not provide extra benefit in this group
of patients with stable angina pectoris receiving standard medical treatment in terms of
24 months major adverse outcomes. (Cardiol J 2008; 15: 226–229)
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Introduction
Percutaneous coronary intervention (PCI) is
commonly used in patients with acute coronary
syndrome and patients with stable angina pectoris.
Although PCI reduces the incidence of death and
myocardial infarction in patients who present with
acute coronary syndromes [1, 2], the long term ef-
fects of PCI in patients with stable angina pectoris
need further elucidation [3]. The present study was
designed to assess the long term outcome in pa-
tients with stable angina pectoris treated with or
without PCI on top of optimal medical therapy. The
primary end-point was major adverse cardiac event
including: fatal or non-fatal myocardial infarction,
death of any cause, repeat target lesion revascula-
rization (either by PCI or coronary artery bypass
graft surgery) and re-hospitalization.
Methods
Study population
Patients with stable angina pectoris and proxi-
mal coronary stenosis of at least 70% in at least one
of major epicardial coronary arteries, who were
admitted to our hospital from June 2003 to June
2005 were included in this study. Exclusion crite-
ria included acute coronary syndrome, refractory
heart failure or cardiogenic shock, ejection fraction
of less than 30%, or revascularization within the
preceding 6 months. The study was approved by the
institutional ethics committee for human subjects.
Informed consent was obtained from all patients.
A total of 80 patients were included in this study.
Thirty one patients received PCI on top of standard
medical treatment and 49 patients received stan-
dard medical treatment alone. Patient selection for
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PCI was based on patient preference rather than
clinical or angiographic data. All patients were re-
ceiving optimal medical treatment and all patients
completed the 24-month follow-up.
According to current guidelines, patients un-
dergoing PCI received aspirin and clopidogrel. Pa-
tients implanted with bare metal stents [BMS, Mu-
tilinkvision, zata (Guidant), Coroflex/Theca (Braun),
S7 (Medtronic)] were treated with clopidogrel
(75 mg/d) for at least 3 months and patients implan-
ted with drug eluting stents [DES, Cypher (Cordis),
Firebird (Microport)] were treated with clopidogrel
(75 mg/d) for at least 9 months and all patients re-
ceived life-long aspirin (100 mg/d) if not contrain-
dicated.
Percutaneous transluminal
intervention procedure
Percutaneous coronary intervention procedu-
res were performed according to standard clinical
practice either by radial or by femoral approach.
Lesion length, % of stenosis and lesion type were
evaluated with on-line quantitative coronary angio-
graphy according to ACC/AHA guidelines [4]. All
patients received aspirin (100–300 mg/d), clopido-
grel (300 mg/d) and nitrate before the procedure,
and 10,000 IU of heparin was administered intra-
venously at the beginning of the procedure, follo-
wed by additional boluses as needed to maintain the
clotting time at 300 s.
Follow-up
All patients were seen in an outpatient facility or
contacted by telephone monthly after discharge. Data
on major adverse cardiac events (MACE), including
fatal or non-fatal myocardial infarction, death of car-
diac or non-cardiac origin, repeat target lesion reva-
scularization by PCI or coronary artery bypass graft
surgery and re-hospitalization were collected.
Statistic analysis
Continuous variables were expressed as mean
± SD and unpaired Student’s t-test was used for
comparison of continuous parameters between gro-
ups. Categorical data were compared using the
c2 test. Results were considered statistically signi-
ficant when p value was < 0.05.
Results
Baseline characteristics
Age, gender and risk factors for coronary he-
art disease were similar between the two groups
(Table 1).
Angiographic characteristics
Successful coronary angiogram was achieved
in all patients without major complications.
Number of diseased vessels, lesion type and
location, % of stenosis and stenosis length were all
comparable between the two groups (Table 2).
Stent implantation
Thirty-one out of 80 patients underwent stent
implantations (14 with single vessel disease, 8 with
double vessel disease and 9 with triple vessel dise-
ase). Fifty-eight stents were implanted in 54 lesions
[19 DES stents in 17 lesions (3 for type A lesion,
10 for type B, 4 for type C) and 39 BMS stents in
37 lesions (29 for type A, 7 for type B, 1 for type C)].
Type B and C lesions were implanted chiefly with
DES while most of type A lesions were implanted
Table 1. Baseline clinical characteristics.
Medication PCI
(n = 49)  (n = 31)
Age (year) 65.8 ± 5.8 64.4 ± 5.4
Male 28 (57.1%) 17 (54.8%)
Hypertension 39 (79.6%) 26 (83.9%)
Diabetes 10 (20.4%) 8 (25.8%)
Hyperlipidemia 43 (87.8%) 27 (87.1%)
Smoking 18 (36.7%) 12 (38.7%)
Family history 13 (26.5%) 10 (32.3%)
PCI — percutaneous coronary intervention
Table 2. Angiographic characteristics.
Medication PCI
(n = 49) (n = 31)
No. of diseased vessels:
   One 23 (46.9%) 14 (45.2%)
   Two 13 (26.5%) 8 (25.8%)
   Three 13 (26.5%) 9 (29.0%)
Lesion type:
   A 29 (44±57.1) 19 (32 ±59.3)
   B 13 (24±31.2) 8 (17 ±31.5)
   C 7 (9±11.7) 4 (5 ±9.3)
Lesion location:
   LAD 36 (38±49.4) 25 (25 ±46.3)
   LCx 15 (17±22.1) 10 (14 ±25.9)
   RCA 17 (22±28.6) 13 (15 ±27.8)
Stenosis (%) 75±6.8 77 ±6.0
Lesion length [mm] 13.58±6.29 13.47 ±5.52
PCI — percutaneous coronary intervention;  LAD — left anterior
descending; LCx — left circumflex; RCA — right coronary artery
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with BMS (all p < 0.05, Table 3). Lesion location,
% of stenosis, reference vessel diameter and stent
diameter were comparable between patients who
received BMS and DES, while lesion length and
stent length were significantly greater in DES gro-
up (p < 0.05, Table 3).
Medication and follow-up results
Medical treatment was similar between the two
groups except that there was significantly more
nitrate use in the medical treatment group during
the 24-month follow-up period (Table 4). Mortality
rate during follow-up was similar between the two
groups (p > 0.05); 1 patient in the PCI group died
of cerebral stroke (1/31, 3.2%) at 19 months post
PCI and 3 patients (3/49, 6.1%) in the medical
treatment group died of acute myocardial infarction
(at 12 months), lung cancer (at 16 months) and ce-
rebral stroke (at 18 months), respectively. Inciden-
ce of total MACE was similar between the two gro-
ups (p > 0.05, Table 5). Incidence of total MACE
between BMS and DES was also similar (3/9 vs.
4/18, p = 0.384).
Discussion
Our study demonstrates that the clinical effi-
ciency of optimal medical treatment versus PCI on
top of medical treatment is similar during the
24-month follow-up in patients with stable angina
pectoris.
Table 3. Stent implantation.
DES BMS
(n = 19)  (n = 39)
Lesion type:
   A 3 (15.8%) 29 (74.3%)*
   B 12 (63.2%) 9 (23.1%)*
   C 4 (21.1%) 1 (2.6%)*
Lesion location:
   LAD 9 (47.4%) 18 (46.2%)
   LCx 5 (26.3%) 10 (25.6%)
   RCA 5 (26.3%) 11 (28.2%)
Stenosis (%) 78±6.2 76±5.8
Lesion length [mm] 17.57±6.08 11.47±4.96*
Stent length [mm] 19.95±5.49 13.87±4.62*
Stent diameter [mm] 2.95±0.23 3.08±0.29
Reference vessel  3.06±0.24 3.27±0.28
diameter [mm]
*p < 0.05 vs. DES; DES — drug eluting stent; BMS — bare metal
stent; LAD — left anterior descending; LCx — left circumflex;
RCA — right coronary artery
Table 5. Clinical follow up
Medication (n = 49) PCI (n = 31)
12 month 24 month  12 month 24 month
MACE 8 (16.3%) 11 (22.4%) 4 (12.9%) 7 (22.6%)
Fatal myocardial infarction 1 (2.0%) 1 (2.0%) 0 (0%)  0 (0%)
Nonfatal myocardial infarction 0 (0%) 1 (2.0%) 0 (0%) 0 (0%)
Noncardiac death 0 (0%) 2 (4.1%) 0 (0%) 1 (3.2%)
Re-hospitalization 7 (14.3%)  8 (16.3%) 4 (12.9%) 6 (19.4%)
PCI — percutaneous coronary intervention; MACE — major adverse cardiac events
Table 4. Drug use in-hospital and during follow up
Medication only (n = 49) PCI (n = 31)
In-hospital 24 months In-hospital 24 months
Nitrates 44 (89.8%) 36 (73.5%) 28 (90.3%) 17 (54.8%)*
Beta-blocker 27 (55.1%) 27 (55.1%) 18 (58.1%) 17 (54.8%)
Aspirin 49 (100%) 49 (100%) 31 (100%) 31 (100%)
Ca-antagonist 24 (49%) 24 (49%) 14 (45.2%) 14 (45.2%)
ACEI/ARB 43 (87.8%) 42 (85.7%) 29 (93.5%) 28 (90.3%)
Statin 47 (95.9%) 46 (93.8%) 30 (96.7%) 30 (96.7%)
*p < 0.05 vs. medication; PCI — percutaneous coronary intervention; ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin
receptor blocking agents
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The reason for the absence of the extra bene-
fits in patients with stable angina pectoris receiving
PCI could be partly explained by the plaque charac-
teristics in these patients. It was shown that coro-
nary plaques in patients with stable angina pecto-
ris are mostly stable plaques characterized by thick
fibrous caps, small lipid cores, more smooth-muscle
cells, fewer macrophages, and more collagen.
Such lesions typically result in ischemia and stable
angina symptoms but rarely cause acute coronary
syndromes [5, 6]. It is plaque characteristics rather
than the degree of stenosis that are the major de-
terminants of the development of an acute corona-
ry syndrome. In another respect, the rapid progress
of modern medical therapy for the treatment of co-
ronary heart disease significantly improved the pro-
gnosis. In the preceding 3 decades, multiple large,
well designed, randomized clinical trials have esta-
blished a survival benefit for 4 different classes of
drugs among a broad spectrum of coronary artery
disease patients. Aspirin; lipid lowering drugs
(especially statins); beta-blockers; and angiotensin-
converting-enzyme inhibitors and/or angiotensin
receptor blocking agents; have all been shown to
enhance survival, as well as reduce other objective
adverse outcomes of coronary artery disease [7].
Consistent with the recently reported study of 2287
patients [8], our findings support the current guide-
lines [9, 10], in that the optimal medical therapy wi-
thout routine PCI can be implemented safely in the
majority of patients with stable coronary artery di-
sease. Moreover, experimental and clinical studies
have shown the beneficial role of modern medical
therapy on plaque stability [11]. It is of note that
a subset of patients with stable angina pectoris mi-
ght need PCI for symptom control and some pa-
tients might develop acute coronary syndrome
which also warrant PCI during the disease process
and these patients need to be carefully monitored
and PCI should be performed when indicated.
Most of the patients in the present study were
aged around 65 years and hence most patients were
free of active occupational stress (in contrast to
younger patients with initial diagnosis of acute co-
ronary syndrome who are usually treated with PCI).
Some factors might have influenced patient prefe-
rence towards the PCI treatment: fear of PCI, phy-
sical activity level, financial as well as educational
status. Subgroup analysis might have been helpful
to elucidate the possible associations concerning
patient preference with regard to PCI treatment,
however, this could not be answered by the present
study due to limited patient number.
Conclusions
In conclusion, at present, medical therapy is
a safe and effective treatment option for patients with
stable angina pectoris and PCI on top of medical the-
rapy does not provide extra benefit in these patients.
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